Pharmacological activation of TRPV4 by GSK1016790A in TECs normalizes tube formation in vitro and tumor angiogenesis in vivo, which reduces tumor growth in combination with cisplatin [306]. The gene discussed is TRPV4; the disease is neoplasm.